Janux Therapeutics Stock Cash Per Share

JANX Stock  USD 32.01  0.59  1.81%   
Janux Therapeutics fundamentals help investors to digest information that contributes to Janux Therapeutics' financial success or failures. It also enables traders to predict the movement of Janux Stock. The fundamental analysis module provides a way to measure Janux Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Janux Therapeutics stock.
Last ReportedProjected for Next Year
Cash Per Share 19.07  20.03 
Cash Per Share is likely to rise to 20.03 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Janux Therapeutics Company Cash Per Share Analysis

Janux Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

 = 

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Janux Therapeutics Cash Per Share

    
  8.15 X  
Most of Janux Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Janux Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Janux Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Janux Therapeutics is extremely important. It helps to project a fair market value of Janux Stock properly, considering its historical fundamentals such as Cash Per Share. Since Janux Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Janux Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Janux Therapeutics' interrelated accounts and indicators.
1.00.97-0.48-0.891.00.81.0-0.411.01.01.0-0.811.00.870.530.69
1.00.97-0.49-0.881.00.771.0-0.411.01.01.0-0.81.00.850.540.68
0.970.97-0.44-0.90.970.760.97-0.590.970.960.97-0.820.960.90.550.72
-0.48-0.49-0.440.1-0.47-0.27-0.49-0.19-0.5-0.44-0.50.6-0.44-0.13-0.930.12
-0.89-0.88-0.90.1-0.89-0.86-0.880.62-0.88-0.91-0.880.7-0.91-0.98-0.23-0.81
1.01.00.97-0.47-0.890.81.0-0.431.01.01.0-0.831.00.860.510.7
0.80.770.76-0.27-0.860.80.77-0.430.780.810.78-0.80.810.870.310.72
1.01.00.97-0.49-0.881.00.77-0.411.01.01.0-0.81.00.850.540.68
-0.41-0.41-0.59-0.190.62-0.43-0.43-0.41-0.41-0.42-0.410.4-0.42-0.69-0.01-0.8
1.01.00.97-0.5-0.881.00.781.0-0.411.01.0-0.821.00.850.550.68
1.01.00.96-0.44-0.911.00.811.0-0.421.01.0-0.791.00.880.490.72
1.01.00.97-0.5-0.881.00.781.0-0.411.01.0-0.821.00.850.550.68
-0.81-0.8-0.820.60.7-0.83-0.8-0.80.4-0.82-0.79-0.82-0.79-0.68-0.53-0.51
1.01.00.96-0.44-0.911.00.811.0-0.421.01.01.0-0.790.880.490.72
0.870.850.9-0.13-0.980.860.870.85-0.690.850.880.85-0.680.880.30.85
0.530.540.55-0.93-0.230.510.310.54-0.010.550.490.55-0.530.490.3-0.01
0.690.680.720.12-0.810.70.720.68-0.80.680.720.68-0.510.720.85-0.01
Click cells to compare fundamentals

Janux Cash Per Share Historical Pattern

Today, most investors in Janux Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Janux Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Janux Therapeutics cash per share as a starting point in their analysis.
   Janux Therapeutics Cash Per Share   
       Timeline  
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Competition

Janux Common Stock Shares Outstanding

Common Stock Shares Outstanding

46.19 Million

At this time, Janux Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.
In accordance with the recently published financial statements, Janux Therapeutics has a Cash Per Share of 8.15 times. This is 87.36% higher than that of the Biotechnology sector and 88.22% higher than that of the Health Care industry. The cash per share for all United States stocks is 62.67% lower than that of the firm.

Janux Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Janux Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Janux Therapeutics could also be used in its relative valuation, which is a method of valuing Janux Therapeutics by comparing valuation metrics of similar companies.
8.158.378.226.22100%
Janux Therapeutics is currently under evaluation in cash per share category among its peers.

Janux Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Janux Therapeutics from analyzing Janux Therapeutics' financial statements. These drivers represent accounts that assess Janux Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Janux Therapeutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Enterprise Value1.0B778.3M520.0M477.6M2.5B2.6B

Janux Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Janux Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Janux Therapeutics' managers, analysts, and investors.
59.4%
Environmental
Governance
Social

Janux Fundamentals

Return On Equity-0.12
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-140%-120%-100%-80%-60%-40%-20%
Return On Asset-0.0993
Operating Margin(81.64) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10%-5%0%5%
Current Valuation1.25 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Shares Outstanding58.63 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5%10%15%20%
Shares Owned By Insiders7.22 %
Shares Owned By Institutions92.78 %
Number Of Shares Shorted9.09 M
Price To Book2.87 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales143.83 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%
Revenue8.08 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit(46.77 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-150,000%-100,000%-50,000%0%
EBITDA(71.02 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%
Net Income(58.29 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Cash And Equivalents338.76 M
Cash Per Share8.15 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000%40,000%60,000%80,000%100,000%120,000%
Total Debt24.54 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%400%500%600%
Debt To Equity0.07 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Current Ratio21.08 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%
Book Value Per Share12.54 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10,000%-8,000%-6,000%-4,000%-2,000%0%
Cash Flow From Operations(50.58 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Short Ratio9.48 X
Earnings Per Share(1.17) X
Price To Earnings To Growth(0.98) X
Target Price89.08
Number Of Employees76
Beta3.16
Market Capitalization1.88 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Total Asset380.41 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%50,000%60,000%
Retained Earnings(168.76 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Working Capital336.21 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset380.41 M

About Janux Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Janux Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Janux Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Janux Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.